OPKO Health Q3 Earnings Ahead Of Expectations
OPKO Health Inc (NASDAQ:OPK) reported Q3 revenues were down 10% Y/Y to $385.8 million, beating the consensus of $302.27 million.…
OPKO Health Q3 EPS $0.04 Beats $(0.01) Estimate, Sales $385.80M Beat $302.27M Estimate
OPKO Health (NASDAQ:OPK) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.01) by 500 percent. This is unchanged from the same period last year. The company reported
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell
• LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.
Taysha Gene Therapies Announces Sponsored Genetic Testing For Giant Axonal Neuropathy In Partnership With GeneDx As Well As A Collaboration with Hereditary Neuropathy Foundation And Charcot-Marie-Tooth Association Centers Of Excellence
GeneDx's Hereditary Neuropathy Panel will be available free of charge to individuals at risk for or suspected of having GAN
Taysha will collaborate with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth
Pfizer’s Growth Hormone Candidate FDA Review Pushed By 3 Months
Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag.
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
Rite Air Reports Partnership With US Dept. Of Health And Human Services, BioReference Labs, New York State For ‘Back To School’ COVID-19 Testing Program
Rite Aid (NYSE:RAD) and the U.S. Department of Health and Human Services (HHS), together with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced a ‘Back to School’ COVID-19